Status:
ENROLLING_BY_INVITATION
Brain Stimulation and Attention Control in Children With ADHD
Lead Sponsor:
Neurolab Plus
Collaborating Sponsors:
Al-Farabi Kazakh National University (KazNU)
Conditions:
ADHD - Attention Deficit Disorder With Hyperactivity
Eligibility:
All Genders
6-12 years
Phase:
NA
Brief Summary
The goal of this clinical trial is to learn if brain stimulation can help children ages 6 to 12 with attention-deficit/hyperactivity disorder (ADHD) improve their attention and self-control. The main ...
Detailed Description
This study explores whether noninvasive brain stimulation can improve attention control in children diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD), and how biological factors such as b...
Eligibility Criteria
Inclusion
- Children aged 6-12 years at the time of enrollment.
- Clinical diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD), any presentation type, confirmed using the Vanderbilt ADHD Diagnostic Parent Rating Scale and clinical interview.
- Intelligence quotient (IQ) ≥ 70 as measured by the General Ability Index (GAI) from the Wechsler Intelligence Scale for Children - Fifth Edition (WISC-V).
- Ability to understand and follow instructions for the Attention Network Test (ANT) and stimulation procedure.
- Stable medication regimen for ADHD (if any) for at least 4 weeks before the start of the study.
- Written informed consent from a parent or legal guardian, and assent from the child when appropriate.
Exclusion
- History of epilepsy, seizures, or abnormal EEG suggestive of seizure risk.
- Presence of metal implants, devices, or foreign bodies in or near the head (except dental fillings) that are contraindicated for TMS or MRI.
- Serious neurological disorders other than ADHD (e.g., cerebral palsy, brain injury, neurodegenerative disease).
- Severe psychiatric disorders requiring hospitalization or urgent intervention.
- Current or past history of significant head trauma with loss of consciousness \> 5 minutes.
- Uncorrected hearing or vision problems that could interfere with task performance.
Key Trial Info
Start Date :
September 4 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2026
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT07182344
Start Date
September 4 2025
End Date
June 1 2026
Last Update
September 19 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Neurolab Plus
Almaty, Kazakhstan, 050000
2
Non-profit joint-stock company "Al-Farabi Kazakh National University"
Almaty, Kazakhstan, 050040